Nvidia and a basket of large caps set the tone as markets weigh stronger-than-expected July PCE and upcoming earnings

U.S. stocks were modestly lower on Wednesday as investors digested a July inflation update that pointed to somewhat stronger price pressures than expected and looked ahead to a key earnings event for Nvidia.

The market mood shifted after the personal consumption expenditures price index, or PCE, for July was reported as a bit stronger than forecasts. PCE is a closely watched measure of inflation based on consumer spending, and it can influence expectations for the Federal Reserve’s path for interest rates.

Against that backdrop, the day’s trading focus centered on Nvidia, which was set to report earnings soon. Nvidia’s results are widely treated as a high-announcement read on demand for its AI-related chips and related data center infrastructure, so investors often react sharply to both the timing and the substance of the release.

The broader “stocks to watch” roundup also pointed to several other names, including Meta, Revolution Medicines, Abercrombie, Intuit, Salesforce, and Moderna. In a market like this, the combination of an inflation-driven macro backdrop and company-specific catalysts can help explain why investors rotate quickly between sectors even when the overall direction is muted.

For companies tied to consumer spending and discretionary demand, the inflation data matters because it can affect how much room households have for purchases and how businesses price goods and services. Even without specific figures in the roundup, investors tend to interpret stronger-than-expected inflation as a reminder that cost pressures and pricing power may move unevenly across the economy.

For technology and software companies in the group, the rate outlook is also relevant. Expectations around interest rates can shape how investors value future cash flows, particularly for companies whose growth prospects depend on sustained enterprise and advertising spending.

On the healthcare side, Moderna’s inclusion in the roundup reflects how earnings and guidance timing, along with broader risk appetite, can move biotech and vaccine developers even when near-term fundamentals are driven by pipelines rather than day-to-day sales patterns.

What remains unclear from the published roundup is the extent of each individual stock’s move on Wednesday and whether any of the companies provided additional forward-looking disclosures in the near term beyond what was already scheduled. The report also does not specify the magnitude of the PCE surprise or provide the precise timing of each earnings or corporate update it references.